-
October 28, 2020 | Synspira Therapeutics Adds Drucy Borowitz, MD, to Board of Directors
-
October 20, 2020 | Synspira Therapeutics Announces Expanded Agreement with Cystic Fibrosis Foundation to Advance Promising Treatments for Cystic Fibrosis
-
February 12, 2020 | Synspira Therapeutics and Cystic Fibrosis Foundation Sign Agreement to Develop Broad-spectrum Enzyme Replacement for Malabsorption Syndromes
-
October 28, 2019 | Synspira Therapeutics Appoints Industry Leaders Dr. Alexey Margolin And Robert K. Coughlin To Board Of Directors
-
April 23, 2019 | Synspira Therapeutics SNSP 113 Demonstrates Improvement in Abnormal Cystic Fibrosis Mucus and Pulmonary Disease
-
April 10, 2019 | Synspira Therapeutics Receives Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis in the European Union
-
March 27, 2019 | Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer
-
October 11, 2018 | Synspira Receives U.S. FDA Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis
-
August 09, 2018 | Synspira’s PAAG Therapy Demonstrates Persistence Against Pseudomonas aeruginosa Persister Cells
-
January 17, 2018 | Synspira’s Novel Glycopolymer Proves Effective Against Antibiotic Resistance
-
January 03, 2018 | Synspira Announces $3 Million Development Award from Cystic Fibrosis Foundation
-
November 02, 2017 | Synspira Announces Data for Lead Candidate at the 31st Annual North American Cystic Fibrosis Conference
-
October 18, 2017 | Synspira Announces First Patient Dosed in Phase 1a Study of SNSP113 in Cystic Fibrosis
-
July 12, 2017 | Synspira’s Novel Glycopolymer Improves Effectiveness of Antibiotics Against Drug-resistant Bacteria Associated with Cystic Fibrosis
-
June 29, 2017 | Synspira Announces $8 Million in Funding and Board of Directors
Toggle navigation